Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07286357 · ClinicalTrials.gov registry record
A Data Collection Protocol to Evaluate the Real World Usage of the Orthofix AccelStim Device to Treat Fresh Metatarsal Fractures
A clinical trial of Metatarsal Fracture, sponsored by Orthofix.
- Active
- Registry status
- 100
- Enrollment target
- 3
- Study locations
NCT07286357: Active study of Metatarsal Fracture, sponsored by Orthofix.
NCT07286357 is a study of Metatarsal Fracture that is active but no longer recruiting, run by Orthofix. The registered enrollment target is 100 participants. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07286357, a study of Metatarsal Fracture, is active but no longer recruiting, sponsored by Orthofix.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study examines the effect of using the AccelStim bone growth stimulator on subjects undergoing treatment for fresh metatarsal fractures.
Primary Outcome
Quantitative and qualitative assessments of clinical and radiographic healing (as available per standard of care)
Conditions Studied
Interventions
- DEVICE AccelStim (LIPUS)
Study Locations (3)
Illinois
- Northwestern - Evanston
- Endeavor Health - Mount Prospect
Maryland
- Precision Orthopedics - Laurel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2026-06-30 |
What the registry record for NCT07286357 still lists
NCT07286357 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Metatarsal Fracture appearing as the primary indexed condition, and to 1 intervention - of which AccelStim (LIPUS) is the first listed.
NCT07286357 reports a single indexed study location in Illinois, Maryland.
Frequently Asked Questions
What is clinical trial NCT07286357 about?
NCT07286357 is a clinical study titled "A Data Collection Protocol to Evaluate the Real World Usage of the Orthofix AccelStim Device to Treat Fresh Metatarsal Fractures". This study examines the effect of using the AccelStim bone growth stimulator on subjects undergoing treatment for fresh metatarsal fractures.
What is the current status of trial NCT07286357?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2025-05-30. Estimated completion is 2026-06-30.
What conditions does trial NCT07286357 study?
This clinical trial studies the following conditions: Metatarsal Fracture.
What interventions are being tested in trial NCT07286357?
The interventions under investigation include: AccelStim (LIPUS) (DEVICE).
Who is sponsoring clinical trial NCT07286357?
This trial is sponsored by Orthofix, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07286357 being conducted?
This trial has 3 study locations across Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI